Chiasma Inc Equity-NMS: CHMA

Healthcare

Biotechnology

Buy/Sell an entire stock
or a fraction.

Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly

Loading, Please wait...

Error in Fetching Data, Please retry later.

No data available.

Previous close :

5Y :

-21.38%

What is the share price of Chiasma Inc today?

Chiasma Inc (CHMA) share price as of May 1, 2025, is $3.76. If you are investing from India, you can always check the valuation in the INR before investing.

Can Indian Investors purchase shares of Chiasma Inc?

Yes, Indian Investors can invest in the Chiasma Inc (CHMA) Share by opening an international trading account with Angel One.

How can I purchase Chiasma Inc shares in India?

Purchasing Chiasma Inc (CHMA) share from India can be done by:

Directly: By opening an international trading account with Angel One. The process would include KYC verification.
The account activation takes a few minutes to a few hours, after which you can start buying Chiasma Inc (CHMA) by making deposits in US dollars.
Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.

Can I buy Fractional shares of Chiasma Inc?

Yes, you can purchase fractional shares of Chiasma Inc (CHMA) or any other US company shares in Angel One for any dollar amount.

What is the market capitalization value of Chiasma Inc?

The market capitalization of Chiasma Inc on May 1, 2025, is $0.

In which sector Chiasma Inc belongs?

Chiasma Inc operates in the Healthcare sector, specifically in the Biotechnology industry.

What documents are required to invest in Chiasma Inc stocks?

In order to invest in Chiasma Inc (CHMA) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.)

From start to end, the process is digital and can be seamless.

Chiasma, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion. The Company is developing octreotide capsules as a liquid-filled solid gelatin capsule formulation, which is intended to be taken over twice a day. The Company's TPE technology enhances the absorption through the intestinal wall of drugs. The Company also focuses on developing CH2 for Orphan indication.